The use of 13C (heavy) leucine infusions to label all newly synthesized proteins, including APP, in pre‐symptomatic subjects with presenilin mutations and their non‐carrier siblings confirmed the extensive data in cultures and mouse models that these AD‐causing mutations increase relative Aβ42 production (Potter et al, 2013). Here, APP is linked to Alzheimer disease.